| [1] |
Barondes SH, Cooper DN, Gitt MA, et al. Galectins: structure and function of a large family of animal lectins [J]. J Biol Chem, 1994, 269(33):20807-20810.
|
| [2] |
Leffler H, Carlsson S, Hedlund M, et al. Introduction to galectins [J]. Glycoconj J, 2002, 19(7-9):433-440.
|
| [3] |
Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential [J]. Expert Rev Mol Med, 2008, 10:e17.
|
| [4] |
Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis [J]. Am J Pathol, 2008, 172(2):288-298.
|
| [5] |
Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia [J]. J Lab Clin Med, 2004, 143(5):269-283.
|
| [6] |
Lopez E, Del PV, Miguel T, et al. Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model [J]. J Immunol, 2006, 176(3):1943-1950.
|
| [7] |
Aksan G, Gedikli O, Keskin K, et al. Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis? [J]. J Investig Med, 2016, 64(3):764-770.
|
| [8] |
Gonzalez GE, Rhaleb NE, D′Ambrosio MA, et al. Cardiac-deleterious role of galectin-3 in chronic angiotensin Ⅱ-induced hypertension [J]. Am J Physiol Heart Circ Physiol, 2016, 311(5):H1287-H1296.
|
| [9] |
Imran TF, Shin HJ, Mathenge N, et al. Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population [J]. Am J Cardiol, 2017, 119(1):57-64.
|
| [10] |
Campo VL, Marchiori MF, Rodrigues LC, et al. Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update [J]. Glycoconj J, 2016, 33(6):853-876.
|
| [11] |
Pugliese G, Iacobini C, Pesce CM, et al. Galectin-3: an emerging all-out player in metabolic disorders and their complications [J]. Glycobiology, 2015, 25(2):136-150.
|
| [12] |
Rasmussen NS, Nielsen CT, Houen G, et al. Humoral markers of active Epstein-Barr virus infection associate with anti-extractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus [J]. Lupus, 2016, 25(14):1567-1576.
|
| [13] |
Winyard PJ, Bao Q, Hughes RC, et al. Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases [J]. J Am Soc Nephrol, 1997, 8(11):1647-1657.
|
| [14] |
Bichara M, Attmane-Elakeb A, Brown D, et al. Exploring the role of galectin 3 in kidney function: a genetic approach [J]. Glycobiology, 2006, 16(1):36-45.
|
| [15] |
Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies [J]. J Pathol, 1999, 187(4):481-489.
|
| [16] |
Yilmaz H, Inan O, Darcin T, et al. Serum galectin-3 levels were associated with proteinuria in patients with familial mediterranean fever [J]. Clin Exp Nephrol, 2015, 19(3):436-442.
|
| [17] |
O′Seaghdha CM, Hwang SJ, Ho JE, et al. Elevated galectin-3 precedes the development of CKD [J]. J Am Soc Nephrol, 2013, 24(9):1470-1477.
|
| [18] |
Rebholz CM, Selvin E, Liang M, et al. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease [J]. Kidney Int, 2018, 93(1):252-259.
|
| [19] |
Tan K, Cheung CL, Lee A, et al. Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus [J]. Diabetologia, 2018, 61(5):1212-1219.
|
| [20] |
Drechsler C, Delgado G, Wanner C, et al. Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D Studies [J]. J Am Soc Nephrol, 2015, 26(9):2213-2221.
|
| [21] |
Fernandes BA, Campanhole G, Wang PH, et al. A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury [J]. Transpl Int, 2008, 21(10):999-1007.
|
| [22] |
Vansthertem D, Cludts S, Nonclercq D, et al. Immunohistochemical localization of galectins-1 and -3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat [J]. Histol Histopathol, 2010, 25(11):1417-1429.
|
| [23] |
Nishiyama J, Kobayashi S, Ishida A, et al. Up-regulation of galectin-3 in acute renal failure of the rat [J]. Am J Pathol, 2000, 157(3):815-823.
|
| [24] |
Dang Z, MacKinnon A, Marson LP, et al. Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3 [J]. Transplantation, 2012, 93(5):477-484.
|
| [25] |
Tan R, Liu X, Wang J, et al. Alternations of galectin levels after renal transplantation [J]. Clin Biochem, 2014, 47(15):83-88.
|
| [26] |
Martinez-Martinez E, Ibarrola J, Fernandez-Celis A, et al. Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats [J]. J Hypertens, 2018, 36(2):368-376.
|
| [27] |
Frenay AR, Yu L, van der Velde AR, et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy [J]. Am J Physiol Renal Physiol, 2015, 308(5):F500-F509.
|
| [28] |
Shen H, Wang J, Min J, et al. Activation of TGF-beta1/alpha-SMA/Col I profibrotic pathway in fibroblasts by galectin-3 contributes to atrial fibrosis in experimental models and patients [J]. Cell Physiol Biochem, 2018, 47(2):851-863.
|
| [29] |
Chen WS, Cao Z, Leffler H, et al. Galectin-3 inhibition by a small-molecule inhibitor reduces both pathological corneal neovascularization and fibrosis [J]. Invest Ophthalmol Vis Sci, 2017, 58(1):9-20.
|
| [30] |
Streetly MJ, Maharaj L, Joel S, et al. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death [J]. Blood, 2010, 115(19):3939-3948.
|